Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Treatment of Early Diagnosed HCV Infection in Hemodialyzed Patients with Interferon-α. Treatment of Hepatitis C

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Acute and early diagnosed hepatitis C virus (HCV) infections are rare diagnoses. Patients on regular dialysis treatment (RDT) are at risk of acquiring HCV infection. Aims of the Study: (1) To determine the efficacy and safety of two-phase induction treatment of acute and early diagnosed HCV infections in patients on RDT, and (2) to establish the importance of serum HCV RNA testing at defined time points of treatment for the prediction of the therapeutic effect. Therapeutic Protocol: Antiviral treatment consisted of two different phases: phase A therapy was interferon (IFN)-α2b 10 million units (MU) s.c. administered daily for 21 days followed by phase B with IFN-α2b 3 MU s.c. administered 3 times weekly for 12 weeks. Results: (1) Efficacy of the treatment: A sustained virological response (SVR) was achieved in a total of 13/18 patients (72%). Safety: We did not observe any serious side effects of the treatment. The most pronounced side effect was the myelosuppression caused by IFN-α. (2) SVR prediction: Patients with negative serum HCV RNA at day 6 achieve SVR more frequently than those with positive HCV RNA at day 6 (p = 0.074). Conclusions: Treatment of acute and early diagnosed HCV infections in hemodialyzed patients is much more effective than treatment of chronic infection. Even relatively high doses of IFN at the beginning of therapy (10 MU daily) are tolerated well by the patients.

          Related collections

          Author and article information

          Journal
          BPU
          Blood Purif
          10.1159/issn.0253-5068
          Blood Purification
          S. Karger AG
          0253-5068
          1421-9735
          2004
          June 2004
          14 January 2005
          : 22
          : 4
          : 344-350
          Affiliations
          aDepartment of Internal Medicine IV; bDepartment of Internal Medicine I; cAliatros Laboratory/Institute of Microbiology, Charles University School of Medicine I, and dBiostatistics and Analysis Unit, Masaryk University Brno, Prague, Czech Republic
          Article
          79871 Blood Purif 2004;22:344–350
          10.1159/000079871
          15258445
          © 2004 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 3, Tables: 4, References: 22, Pages: 7
          Product
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/79871
          Categories
          Original Paper

          Cardiovascular Medicine, Nephrology

          Interferon-α, Acute hepatitis C virus infection

          Comments

          Comment on this article